• The effectiveness use of the «Aflubin» drug in the complex therapy among children with ARVI
en To content

The effectiveness use of the «Aflubin» drug in the complex therapy among children with ARVI

SOVREMENNAYA PEDIATRIYA.2014.6(62):56–61; doi 10.15574/SP.2014.62.56

The effectiveness use of the «Aflubin» drug in the complex therapy among children with ARVI

Kramarev S. A., Zakordonets L. V., Evtushenko V. V., Tolstanova A. N. 
National Medical University named after A.A. Bogomoletz, Kiev, Ukraine 
National Medical University named after Taras Shevchenko, Kyiv, Ukraine

Purpose: to study the efficacy and safety of «Aflubin» drug using in the treatment of the children with ARVI.

Patients and methods: there were observed 75 children with medium severity ARVI in age from 6 months to 17 years and were divided into two age groups: from 6 months to 4 years old and over 4 years. Each age group was isolated by the major group that from the first day of hospitalization received the «Aflubin» drug in the age dose and the control group who received only symptomatic therapy.

Results: it was set that ARVI among children had devolved due to the lower local immunity of mucous membranes of the respiratory tract, that was manifested in a decrease levels at baseline IgA, a-INF and g-INF in saliva. Using the «Aflubin» drug the main symptoms of ARVI severity was significantly reduced by the third day of therapy and disappeared by the fifth day of observation. An immune-modulatory drug activity was shown to increase the synthesis of sIgA in children, s saliva of all age groups and g-interferon among children over four years. In the observation groups the disappearance of the clinical ARVI manifestations outpaced the normalization of an immunological parameters in the saliva.

Conclusions: the clinical and immunological efficacy, the lack of side effects make it possible to recommend the drug «Aflubin» for the ARVI treatment for children of the different age groups.

Key words: ARVI, children, immunological parameters, Aflubin.

1. Ершов ФИ, Киселев ОИ. 2005. Интерфероны и их индукторы (от молекул до лекарств). М, ГЭОТАР-Медиа: 350.

2. Землякова ЭИ, Шакирова ЭМ, Сафина ЛЗ. 2012. Экспертный анализ лечения острых респираторных инфекций участковыми педиатрами. Практич медицина. 7.

3. Иощенко ЕС, Бимбас ЕС, Козлова СН. Способ прогнозирования кариозного процесса у детей. Патент RU 2413230.

4. Кетлинский СА. 2004. Отчет о результатах изучения препарата «Альгирем» у детей с гриппом и ОРВИ. СПб. Институт гриппа: 175.

5. Захарова ИН, Малиновская ВВ, Торшхоева ЛБ и др. 2014. Применение рекомбинантного альфа-2b-интерферона (Виферон) при острых респираторных инфекциях у детей раннего возраста. Эффективная фармакотерапия. 3: 6—14.

6. Чеботарева ТА, Мазанкова ЛН. 2010. Эффективность Виферона в терапии и профилактике гриппа и других ОРВИ у детей. Нов медицины и фармации. 2(307).

7. Fashner J, Ericson K, Werner S. 2012. Treatment of the Common Cold in Children and Adults. Am Fam Physician. 15: 86(2): 153—159.

8. Feverish illness in children assessment and initial management in children younger than 5 years. Clinical Guideline. National Collaborating Centre for Women's and Children's Health. 2007. Published by the RCOG Press at the Royal College of Obstetricians and Gynaecologists.

9. Vareille M, Kieninger E, Edwards MR, Regamey N. 2011. The Airway Epithelium: Soldier in the Fight against Respiratory Viruses. Clinical Microbiology Reviews. 24;1: 210—229. http://dx.doi.org/10.1128/CMR.00014-10; PMid:21233513 PMCid:PMC3021210